resisttb
- Sep 21, 2022
- 1 min read

PAN-TB collaboration to advance investigational TB drug regimens to Phase 2 clinical trials

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development. The collaboration will evaluate whether the novel regimens, which combine registered products and new chemical entities (NCEs), can effectively treat all forms of active pulmonary TB using substantially shorter treatment durations than existing drug regimens, with the goal of identifying a regimen suitable for phase 3 development. Read more here.

Recent Posts

See All

Why is a curable disease allowed to kill millions?

John Green, the author of several books and a longtime supporter of Partners in Health, discusses his time visiting Sierra Leone’s Lakka Government Hospital, a tuberculosis treatment center. He talks

International consensus highlights the importance of molecular testing for MDR-TB

A multidisciplinary group of tuberculosis experts from the TBnet and RESIST-TB networks have reached a consensus on key issues related to the molecular prediction of Mycobacterium tuberculosis antibio

Sweet advance for treatment of children with multi-drug resistant TB

Children with multi-drug resistant tuberculosis (MDR-TB) undergo months of life-saving treatment including many doses of foul-tasting medications, which caregivers often struggle to prepare and admini